iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products
* iX Biopharma will receive an initial US$9 million upfront payment * Eligible for up to US$239 million in development and sales milestone payments * Double digit royalties on future product sales of any licensed product SINGAPORE, Nov. 25, 2021 /PRNewswire/ -- iX Biopharma Ltd (SGX:42C), a ...
iX Biopharma Reports on Outcome of Wafermine End-of-phase 2 Meeting with US FDA
SINGAPORE, Dec. 11, 2019 /PRNewswire/ -- Specialty pharmaceutical company iX Biopharma Ltd(SGX:42C) ("iX Biopharma" or, "the Company") is pleased to announce that it has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Wafermine, a sublin...
First Sublingual Ketamine Drug for Treatment of Acute Pain to be Evaluated in End-of-Phase 2 Meeting with FDA
* Racemic sublingual ketamine, Wafermine, is the first sublingual ketamine drug seeking FDA approval for the treatment of moderate to severe acute pain * Wafermine is a Phase 2-ready drug for treatment resistant depression SINGAPORE, May 21, 2019 /PRNewswire/ -- iX Biopharma Ltd (SGX:42C) anno...
